Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19946423 | 1.00 | ABCB1 (0.48) | ABCB1CYP3A4CYP2C9POLBTAS1R3 | |
| SCHEMBL10147876 | 1.00 | ABCB1 (0.48) | ABCB1CYP3A4CYP2C9POLBTAS1R3 | |
| SCHEMBL13983605 | 0.92 | ABCB1 (0.48) | ABCB1CYP3A4CYP2C9POLBTAS1R3 | |
| SCHEMBL2684130 | 0.92 | ABCB1 (0.58) | ABCB1CYP3A4TAS1R3TAS1R1 | |
| SCHEMBL29786241 | 0.92 | ABCB1 (0.58) | ABCB1CYP3A4TAS1R3TAS1R1 | |
| SCHEMBL2684282 | 0.92 | ABCB1 (0.58) | ABCB1CYP3A4TAS1R3TAS1R1 | |
| SCHEMBL14763458 | 0.92 | ABCB1 (0.58) | ABCB1CYP3A4TAS1R3TAS1R1 | |
| SCHEMBL2682676 | 0.92 | ABCB1 (0.52) | ABCB1CYP3A4 | |
| SCHEMBL2682600 | 0.92 | ABCB1 (0.52) | ABCB1CYP3A4 | |
| SCHEMBL19946415 | 0.92 | ABCB1 (0.52) | ABCB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2017-07-20 | — | — | US | disclosed |
| US-9598355-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598355-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150099636-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-04-09 | — | — | US | disclosed |
| US-8884060-B2 | Process of preparing chiral diacylhydrazine ligands | INTREXON CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120316066-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316066-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
| US-8076517-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076517-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2008153801-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885CYP3A4 2691/4885CYP2C9 4174/4885 |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885CYP3A4 2691/4885CYP2C9 4174/4885 |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885CYP3A4 2691/4885CYP2C9 4174/4885 |
| US-20120316066-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885CYP3A4 2691/4885CYP2C9 4174/4885 |
| US-20150099636-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885CYP3A4 2691/4885CYP2C9 4174/4885 |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885CYP3A4 2691/4885CYP2C9 4174/4885 |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885CYP3A4 2691/4885CYP2C9 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.